In addition, immune checkpoint inhibitors such as atezolizumab [249], cemiplimab [250], and nivolumab plus ipilimumab [251] received FDA approval for treating patients with high PD-L1 expression and no EGFR or ALK genomic tumor aberrations. Here, ALK is linked to neoplasm.